SpotDraft's Series B funding round, spearheaded by Vertex Ventures and Trident Partners, will accelerate the company's global ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...
The contract lifecycle management platform aims to spend this year focusing on growing its talent and continuing to expand AI ...
In a report released today, Gena Wang from Barclays maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price ...
An increase in high-fat, high-fructose foods in people's diets has contributed to a dramatic increase in type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback